KiroVAX 002

Drug Profile

KiroVAX 002

Alternative Names: CT-002; KiroVAX002; TAPA loaded DC vaccine - KiroVAX-002; TAPA loaded dendritic cell vaccine - KiroVAX-002; TAPA pulsed dendritic cell vaccine - KiroVAX-002; TAPA-pulsed DC vaccine - KiroVAX-002; Tumour associated peptide antigen loaded DC vaccine-KiroVAX-002; Tumour associated peptide antigen loaded dendritic cell vaccine - KiroVAX-002; Tumour associated peptide antigen pulsed DC vaccine - KiroVAX-002; Tumour associated peptide antigen pulsed dendritic cell vaccine - KiroVAX-002

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT02223312)
  • 28 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02223312)
  • 01 Sep 2014 Phase-I clinical trials in Solid tumours in USA (SC, Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top